Mittal Gauri, Bisht Manisha, Pai Venkatesh S, Handu Shailendra S
Department of Pharmacology, AIIMS Rishikesh, Veerbhadra Road, Rishikesh, Uttarakhand, India.
Department of General Medicine, AIIMS Rishikesh, Veerbhadra Road, Rishikesh, Uttarakhand, India.
J Family Med Prim Care. 2021 Feb;10(2):745-751. doi: 10.4103/jfmpc.jfmpc_1366_20. Epub 2021 Feb 27.
This study was aimed to analyze the prescription pattern of disease modifying anti-rheumatic drug (DMARD) therapy in patients with rheumatoid arthritis (RA) in a tertiary care teaching hospital in Uttarakhand, India.
This cross-sectional study was conducted in 150 RA patients who were given DMARD therapy. Patient's demographic details, drugs prescribed with their dosage and administration routes and the usage of complementary and alternative medicine (CAM) therapy were recorded to study the prescription pattern.
Overall, 4 DMARDs were prescribed in all the studied patients: Methotrexate ( = 150), hydroxychloroquine ( = 35), leflunomide ( = 5), and adalimumab ( = 1). Single DMARD therapy with methotrexate was prescribed to 110 (73.3%) followed by double therapy with methotrexate + hydroxychloroquine in 35 (23.3%), triple therapy (methotrexate + hydroxychloroquine + leflunomide) in 4 (2.7%) and triple therapy with biological DMARD (methotrexate + hydroxychloroquine + leflunomide + adalimumab) in 1 (0.7%) patient. Adjuvant therapy drugs included: Prednisolone ( = 150), folic acid ( = 150), naproxen ( = 150), calcium ( = 150), vitamin D ( = 150) and indomethacin ( = 40). Of the total, 61.4% patients also took complimentary alternative medicine (CAM) therapy.
Our study concludes that the most commonly prescribed DMARDs in our setting, to patients of RA, in descending order of frequency were methotrexate, followed by hydroxychloroquine, leflunomide and lastly adalimumab. A total of five adjuvant medications were commonly prescribed to all patients. There was a high prevalence of self-medicated CAM therapy in the majority of these patients.
本研究旨在分析印度北阿坎德邦一家三级护理教学医院中类风湿关节炎(RA)患者的改善病情抗风湿药(DMARD)治疗处方模式。
本横断面研究纳入了150例接受DMARD治疗的RA患者。记录患者的人口统计学细节、所开药物及其剂量、给药途径以及补充和替代医学(CAM)疗法的使用情况,以研究处方模式。
总体而言,所有研究患者共开具了4种DMARD:甲氨蝶呤(n = 150)、羟氯喹(n = 35)、来氟米特(n = 5)和阿达木单抗(n = 1)。110例(73.3%)患者接受了甲氨蝶呤单药DMARD治疗,35例(23.3%)患者接受了甲氨蝶呤+羟氯喹联合治疗,4例(2.7%)患者接受了三联疗法(甲氨蝶呤+羟氯喹+来氟米特),1例(0.7%)患者接受了生物DMARD三联疗法(甲氨蝶呤+羟氯喹+来氟米特+阿达木单抗)。辅助治疗药物包括:泼尼松龙(n = 150)、叶酸(n = 150)、萘普生(n = 150)、钙(n = 150)、维生素D(n = 150)和吲哚美辛(n = 40)。总计61.4%的患者还接受了补充替代医学(CAM)疗法。
我们的研究得出结论,在我们的研究环境中,最常给RA患者开具的DMARD按频率降序排列依次为甲氨蝶呤,其次是羟氯喹、来氟米特,最后是阿达木单抗。所有患者普遍共开具了五种辅助药物。这些患者中的大多数自我使用CAM疗法的比例很高。